1. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006; 155:156–159.
Article
2. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Clin Ther. 2010; 32:1681–1703.
Article
3. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989; 21:985–991.
4. Jalal O, Houass S, Laissaoui K, Hocar O, Charioui S, Amal S. Severe psoriasis: 160 cases. Ann Dermatol Venereol. 2005; 132:126–128.
5. Marks J. Erythrodermas and uric acid aberrations in psoriasis. In : Farber EM, Cox AJ, editors. Psoriasis: proceedings of the International Symposium Stanford University. Stanford, CA: Stanford University Press;1971. p. 89–98.
6. Heikkilä H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005; 141:1607–1610.
Article
7. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007; 156:329–336.
Article
8. Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007; 157:828–831.
Article
9. Richetta AG, Maiani E, Carlomagno V, Carboni V, Mattozzi C, Giancristoforo S, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther. 2009; 22:Suppl 1. S16–S18.
Article
10. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010; 162:1144–1146.
Article
11. Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011; 38:1096–1099.
Article
12. Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, et al. Groupe Français de Recherche sur le Psoriasis. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012; 167:417–423.
Article
13. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010; 22:138–142.
Article
14. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005; 124:1275–1283.
Article
15. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl. 2012; 89:90–93.
Article
16. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007; 47:383–396.
Article